Utilization patterns and survival outcomes after wide local excision or Mohs micrographic surgery for Merkel cell carcinoma in the United States, 2004 States, -2009 To the Editor: Although Merkel cell carcinoma (MCC) is often treated with wide local excision (WLE), 1 several studies in the literature have demonstrated the efficacy of Mohs micrographic surgery (MMS) on the basis of local and regional recurrence rates (Supplemental Table I ; available at http://www.jaad.org). Outcome comparisons between MMS and WLE are limited by small sample sizes, short follow-up periods, or lack of assessment of cause-specific survival as the primary end point. Therefore, we used a nationally representative US populationebased database to determine the utilization patterns and survival outcomes of MCC treated with MMS versus with WLE.
We performed a retrospective population-based cohort study from 2004 to 2009 of microscopically confirmed MCC from the Surveillance, Epidemiology and End Results program. Supplemental Table II (available at http://www.jaad.org) provides sociodemographic, clinical, staging, management, and survival characteristics of the study cohort. This study is exempt from institutional review board approval. Table I CI; 1.12-4.07). In accordance with the guidelines for appropriate use, 2 MMS was more likely to be used for MCC on the head or neck. In multivariable Cox survival analysis (Table II) , there was no significant difference in overall and MCC-specific survival between WLE and MMS. Overall and MCC-specific survival were worse if MCC was not treated with surgery when compared with WLE-treated MCC.
Limitations of this study include its retrospective design; lack of measurement of important covariates such as surgical margin of WLE and MMS, use of CK-20 immunostaining during MMS, local and regional recurrence rates, details of radiation therapy (timing, location and dosage), comorbidities, and individual-level socioeconomic factors; lack of independent verification regarding accuracy of pathologic diagnosis; and delayed reporting or underreporting to the Surveillance, Epidemiology and End Results registries. Despite these limitations, the major strengths of the study were use of a large nationally representative quality-controlled population-based database, multivariable analysis controlling for a range of confounders, and use of cause-specific survival as an end point.
Our study provides strong evidence that MMS is a surgical option for MCC, especially for early-stage tumors on the head and neck. The survival outcomes for MMS are comparable to those for WLE. MMS-treated MCCs were less likely to be subjected to sentinel lymph node biopsy between 2004 and 2009. We recommend that surgeons performing Mohs micrographic surgery appropriately refer their patients with MCC for sentinel lymph node biopsy in accordance with National Comprehensive Cancer Network guidelines. 1 Given similar survival outcomes for MCC, future research is warranted regarding the cost differences between MMS and WLE to guide appropriate and cost-effective utilization.
Retrospective effects of the American Joint Committee on Cancer's eighth edition guidelines for staging melanoma
To the Editor: The American Joint Committee on Cancer (AJCC) published the eighth edition of its cancer staging manual in October 2016. 1 In the new evidence-based guidelines, the criteria for classification of stage pT1 melanomas have been modified. The presence of mitoses is no longer a criterion, although it is still recommended that the rate be reported. Lesions are now substaged into pT1a and pT1b categories on the basis of presence or absence of ulceration (as in the previous edition), as well as on the basis of a Breslow depth more or less than 0.8 mm.
2 Nonulcerated melanomas thinner than 0.8 mm are classified as pT1a, and melanomas thicker than 0.8 mm and/or with ulceration are classified as pT1b. Depth may be reported to a 
